Free Trial
→ Did you grab your copy yet? (From Profits Run) (Ad)tc pixel
NASDAQ:NRXS

NeurAxis Earnings Date & Estimates

NeurAxis logo
$7.74 +1.21 (+18.53%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$7.78 +0.04 (+0.52%)
As of 10/15/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeurAxis is estimated to report earnings on Monday, November 9, 2026, before market opens.

Research:ProfileForecast

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from NeurAxis

NeurAxis is expected to post earnings of -$0.21 per share on revenue of $2.10 million.

Consensus Estimates

Consensus EPS
-$0.21
Expected Revenue
$2.10 million

Recent Track Record

Last Reported
Nov 12, 2024
Last Quarter EPS
-$0.25
Last Quarter Revenue
$0.67 million

Prepare for the Earnings Call

NeurAxis Earnings FAQ

NeurAxis (NASDAQ:NRXS) is estimated to report earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect NeurAxis to post earnings of -$0.21 per share for the quarter.

The consensus revenue estimate for NeurAxis is $2.10 million for the quarter.

NeurAxis Earnings Headlines

Aetna deems IB-Stim by NeurAxis medically necessary
October 15 at 1:32 PM  |  tipranks.comhttps://www.tipranks.com/news/the-fly/aetna-deems-ib-stim-by-neuraxis-medically-necessary-thefly-news
NeurAxis Announces Major National Insurer Coverage Expansion for IB-Stim Penetrating 26 Million Medical Plan Members
October 15 at 9:31 AM  |  quiverquant.comQ
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
 |  Banyan Hill Publishing (Ad)
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
October 15 at 9:18 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3381751/0/en/neuraxis-announces-medical-policy-coverage-milestone-expanding-access-to-26-million-additional-covered-lives.html
NeurAxis Declares Q3 Stock Dividend on Preferred Shares
October 14 at 5:31 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuraxis-declares-q3-stock-dividend-on-preferred-shares?utm_source=marketbeat.com&utm_medium=referral
NovoCure (NASDAQ:NVCR) versus NeurAxis (NASDAQ:NRXS) Head-To-Head Analysis
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110894
See More NeurAxis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeurAxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeurAxis and other key companies, straight to your email.

About NeurAxis

NeurAxis (NASDAQ:NRXS) is a medical technology company focused on developing and commercializing neuromodulation therapies for functional gastrointestinal disorders. The company’s primary product is IB-Stim, a minimally invasive device that delivers percutaneous electrical nerve field stimulation through the external ear.

IB-Stim is designed to modulate neural pathways associated with functional abdominal pain and related gastrointestinal symptoms. It has been cleared by the U.S. Food and Drug Administration for use in patients, including adolescents, with functional abdominal pain associated with irritable bowel syndrome. The therapy is administered by qualified healthcare professionals and is intended to complement broader clinical care.

NeurAxis is headquartered in Carmel, Indiana, and primarily serves the U.S. healthcare market through physicians and other medical providers. The company’s activities center on expanding awareness and adoption of its neuromodulation platform in gastroenterology, pain management and related specialties.

View NeurAxis Profile
Earnings Tools